Foundry Partners LLC Purchases 1,730 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Foundry Partners LLC increased its holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 51.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,092 shares of the specialty pharmaceutical company’s stock after acquiring an additional 1,730 shares during the period. Foundry Partners LLC’s holdings in Jazz Pharmaceuticals were worth $627,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of the business. IFP Advisors Inc bought a new position in Jazz Pharmaceuticals in the 4th quarter valued at $25,000. CoreFirst Bank & Trust purchased a new position in shares of Jazz Pharmaceuticals in the 4th quarter worth about $28,000. Allianz SE bought a new position in Jazz Pharmaceuticals during the fourth quarter valued at about $29,000. Jones Financial Companies Lllp increased its holdings in Jazz Pharmaceuticals by 75.1% during the fourth quarter. Jones Financial Companies Lllp now owns 303 shares of the specialty pharmaceutical company’s stock worth $37,000 after buying an additional 130 shares during the last quarter. Finally, UMB Bank n.a. raised its position in Jazz Pharmaceuticals by 70.9% in the fourth quarter. UMB Bank n.a. now owns 311 shares of the specialty pharmaceutical company’s stock worth $38,000 after acquiring an additional 129 shares during the period. 89.14% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on the stock. Royal Bank of Canada reduced their target price on shares of Jazz Pharmaceuticals from $179.00 to $178.00 and set an “outperform” rating for the company in a research report on Wednesday, February 26th. Cantor Fitzgerald lowered Jazz Pharmaceuticals from an “overweight” rating to a “neutral” rating and boosted their target price for the company from $140.00 to $150.00 in a research note on Wednesday, February 26th. HC Wainwright increased their price target on Jazz Pharmaceuticals from $200.00 to $217.00 and gave the stock a “buy” rating in a research note on Monday, March 10th. Morgan Stanley restated an “overweight” rating and issued a $183.00 price objective (up from $175.00) on shares of Jazz Pharmaceuticals in a research note on Friday, March 7th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $210.00 target price on shares of Jazz Pharmaceuticals in a research report on Wednesday, March 5th. One investment analyst has rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $187.71.

Insider Buying and Selling

In other news, CAO Patricia Carr sold 1,140 shares of the stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $137.81, for a total transaction of $157,103.40. Following the transaction, the chief accounting officer now directly owns 7,012 shares in the company, valued at approximately $966,323.72. This represents a 13.98 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Neena M. Patil sold 3,800 shares of the firm’s stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $144.87, for a total value of $550,506.00. Following the transaction, the executive vice president now directly owns 33,318 shares in the company, valued at approximately $4,826,778.66. This represents a 10.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 28,736 shares of company stock worth $4,023,305. Insiders own 4.20% of the company’s stock.

Jazz Pharmaceuticals Stock Performance

NASDAQ:JAZZ opened at $110.04 on Friday. The stock has a market cap of $6.68 billion, a P/E ratio of 15.50, a PEG ratio of 1.04 and a beta of 0.44. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. The business’s 50-day moving average price is $132.27 and its two-hundred day moving average price is $122.91. Jazz Pharmaceuticals plc has a twelve month low of $99.06 and a twelve month high of $148.06.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.